Clinical Trials

31 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05923879 2023-06-28

Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma

30 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05883709 2023-06-01

A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL

15 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05771883 2023-05-24

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

Phase 1/2 Unknown

102 enrolled

Lymphoma, B-Cell

NCT05179733 2023-05-23

The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years

Phase 3 Unknown

280 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05797948 2023-04-04

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase NA Unknown

20 enrolled

Recurrence, Lymphoma, B-Cell

NCT04113226 2023-02-08

Relyage

114 enrolled

LymphoidSarcoma

Recurrence, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT05182957 2023-01-31

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

40 enrolled

Lymphoma, T-Cell, Peripheral

NCT05575973 2022-10-12

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

55 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03891355 2022-09-15

FIL_KLIMT

16 enrolled

Lymphoma, Mantle-Cell

NCT05200312 2022-03-11

ZR2-CHOP

36 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

54 enrolled

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

NCT03837873 2022-01-26

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

118 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04818372 2021-11-12

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Phase 1 Unknown

87 enrolled

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT05076097 2021-11-11

A Study of OLR in First-line Treatment of Mantle Cell Lymphoma

29 enrolled

Lymphoma, Mantle-Cell

NCT05014100 2021-08-27

Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma

55 enrolled

Lymphoma, B-Cell

NCT03949062 2021-02-17

Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL

30 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04025593 2020-11-19

Biomarker Guided Treatment in DLBCL

128 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04604028 2020-10-27

LCMALT

21 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT04544059 2020-09-10

Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma

87 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04432402 2020-06-16

Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

Phase NA Unknown

124 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04040491 2020-05-12

PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma

Phase 4 Unknown

100 enrolled

Lymphoma, T-Cell, Peripheral

NCT04329130 2020-04-24

Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

44 enrolled

LymphoidMyeloidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Peripheral

NCT01619761 2020-02-11

NK Cells in Cord Blood Transplantation

Phase 1 Unknown

13 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04109872 2020-02-05

Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.

25 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT03746223 2019-10-09

Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma

42 enrolled

Intraocular Lymphoma

NCT02060656 2019-09-19

LEGEND

92 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04038411 2019-07-30

PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma

Phase 4 Unknown

50 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT03715296 2019-07-08

Lenalidomide Based Immunotherapy in the Treatment of DLBCL

200 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03715309 2019-07-08

R2 in the Treatment of Follicular Lymphoma

115 enrolled

Lymphoma, Follicular

NCT02354313 2018-02-09

MCL0208

Phase 3 Unknown

300 enrolled

Lymphoma, Mantle-Cell

NCT01412307 2015-08-11

LEBEN

Phase 1/2 Unknown

36 enrolled

Hodgkin Disease

NCT01307592 2014-01-10

Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma